All Blogs

Apr 01, 2022

Treatment-resistant Hypertension: Insights into the Challenges and Solutions


Mar 31, 2022

Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies


Mar 30, 2022

Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022


Mar 29, 2022

Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval


Mar 28, 2022

Examining the Therapeutic Advances in Fabry Disease Treatment Landscape


Mar 25, 2022

Can Dupixent Be A Gamechanger In The Atopic Dermatitis Treatment Landscape?


Mar 24, 2022

Smithfield BioScience and BioCircuit’s Nerve Tape Device; Cynosure-Jeisys Medical’s Partnership; bioMérieux’s VITEK® MS PRIME new MALDI-TOF Mass Spectrometry Identification System; Artio Medical’s Gold Embolization Device; Heartpoint Global’s Implant System; ObvioHealth’s Virtual Urogynecology Clinical Trial


Mar 23, 2022

What are the Top 9 Most Common Food Allergies and How Pharma Companies are Tackling the Crisis?


Mar 22, 2022

Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor


Mar 21, 2022

Role of Mobile Technology in Hemophilia Management